Successful treatment of severe psoriasis with basiliximab, an interleukin‐2 receptor monoclonal antibody
CM Owen, PV Harrison - Clinical and experimental dermatology, 2000 - academic.oup.com
CM Owen, PV Harrison
Clinical and experimental dermatology, 2000•academic.oup.comT‐cell mediated inflammation plays an important role in the aetiology of psoriasis. We
describe a case of severe recalcitrant psoriasis responding well to combined cyclosporin
and basiliximab (Simulect® Novartis Pharmaceuticals UK Ltd), an interleukin‐2 receptor (IL‐
2R; CD25) chimeric monoclonal antibody.
describe a case of severe recalcitrant psoriasis responding well to combined cyclosporin
and basiliximab (Simulect® Novartis Pharmaceuticals UK Ltd), an interleukin‐2 receptor (IL‐
2R; CD25) chimeric monoclonal antibody.
Abstract
T‐cell mediated inflammation plays an important role in the aetiology of psoriasis. We describe a case of severe recalcitrant psoriasis responding well to combined cyclosporin and basiliximab (Simulect® Novartis Pharmaceuticals UK Ltd), an interleukin‐2 receptor (IL‐2R; CD25) chimeric monoclonal antibody.
Oxford University Press